Navigation Links
Obesity Significantly Increases Side Effects of Stereotactic Body Radiation Therapy in Lung Cancer Patients
Date:11/2/2009

npoints high doses of radiation directly on the cancer in a shorter amount of time than traditional treatments. Cancer centers often call the treatments by the brand names of the manufacturers, including Axesse, CyberKnife, Gamma Knife, Novalis, Primatom, Synergy, X-Knife, TomoTherapy and Trilogy. Treatment is typically delivered in 1 to 2 weeks, instead of a period of 6 to 8 weeks.

"SBRT is now being investigated as a replacement to surgery for early-stage lung cancer. If this non-invasive technique is to replace surgery, not only does it need to be effective, but also safe," Dr. Welsh said. "Since this study shows that a 35Gy dose of radiation, obesity, and diabetes increase the risk of developing late negative side effects after high dose radiation, then we can take steps to reduce these side effects."

The study involved 265 patients with tumors within less than 2.5 centimeters of the chest wall, who were treated with SBRT between August 2004 and August 2008. Of these patients, 39 percent developed skin toxicity, while six percent developed acute pain and 22 percent developed chronic pain. In patients who are considered obese, diabetes mellitus was found to be a significant contributing factor in the development of chest pain.

For more information on cancer and stereotactic radiation therapy, visit www.rtanswers.org.

The abstract, "Skin Toxicity And Pain In Patients Treated With Stereotactic Body Radiotherapy," will be presented at a scientific session at 3:20 p.m. on Tuesday, November 3, 2009. To speak to the lead author of the study, James Welsh, M.D., please call Beth Bukata or Nicole Napoli November 1-4, 2009, in the ASTRO Press Room at McCormick Place West at 312-791-7005 or 312-791-7006. You may also e-mail them at '/>"/>

SOURCE American Society for Radiation Oncology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
2. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
3. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
4. A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
5. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
6. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
7. Is Obesity an Oral Bacterial Disease?
8. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
9. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
10. Complications and Costs for Obesity Surgery Declining
11. Obesity Associated With Higher Risk for Urinary Tract Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , 21 de noviembre de 2014 /PRNewswire/ ... ensayos clínicos externalizados y tecnologías eClinical, ha indicado ... de ,seguimiento inteligente, para el seguimiento basado en ... inteligente amplía el concepto del seguimiento basado en ... de las visitas de seguimiento o cambio de ...
(Date:11/22/2014)... Nov. 21, 2014 MEDITE Group acquired by CytoCore, ... and the 3 rd quarter sales ended September 30, ... $448,000 for the nine months ended September 2014 and a ... our 3 rd quarter is usually a seasonable weak ... July into September for many countries worldwide, we are proud ...
(Date:11/22/2014)... Nov. 21, 2014 Many power shifts ... growing influence of patients in the biopharmaceutical market ... Now, more than ever, understanding how to effectively ... products is essential. According to ... benchmarked companies spent about two-thirds of their patient-focused ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2
... , NEW YORK, ... research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164212/Chiral-Technology---International-Technology--Market-Trends.html , The fast developing ... of activity with pharmaceutical companies adding chiral expertise to ...
... , NEW YORK, ... research report is available in its catalogue: , ... of Market Trends & Opportunities , http://www.reportlinker.com/p0164272/Hepatitis-C-Virus-And-Therapeutics---A-Global-Update-of-Market-Trends--Opportunities.html ... years of meager clinical outcomes owing to lack of ...
Cached Medicine Technology:Reportlinker Adds Chiral Technology - International Technology & Market Trends 2Reportlinker Adds Chiral Technology - International Technology & Market Trends 3Reportlinker Adds Chiral Technology - International Technology & Market Trends 4Reportlinker Adds Chiral Technology - International Technology & Market Trends 5Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Hepatitis C Virus and Therapeutics - A Global Update of Market Trends & Opportunities 8
(Date:11/22/2014)... November 22, 2014 Recently, UWDress.com is ... wedding guest dresses . In addition, the company has ... , As a leading online supplier of wedding ... beautiful outfits. The unusual best wedding guest gowns are ... the amazing designs, this new selection is famous for ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 Sandbridge ... equity investments in the consumer brand sector, acquired ... investment will be used to help fund BackJoy’s ... pipeline rollout, particularly its proprietary apparel and footwear ... join BackJoy’s Board of Directors. , BackJoy is ...
(Date:11/22/2014)... “Greenfield Naturals” was featured on NewsWatch as ... features the latest and coolest technology products available to ... NewsWatch, conducted the product review and shared with viewers ... water. , From pollution to hazardous substances in water, ... done to remove these chemicals, especially in water. , ...
(Date:11/22/2014)... 21, 2014 (HealthDay News) -- A clinical trial of ... been halted a year early because the results show ... the disease and reduce the risk of stroke. ... 25 medical centers in the United States and Canada, ... Lung, and Blood Institute (NHLBI). Researchers compared monthly ...
(Date:11/22/2014)... Steven Reinberg HealthDay Reporter ... better when patients are treated in an ambulance by a ... researchers report. The sooner patients get the clot dissolver ... after a stroke, the researchers noted. For the best outcome, ... after stroke symptoms start, the researchers said. "The so-called ...
Breaking Medicine News(10 mins):Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 2Health News:Sandbridge Capital Acquires a Minority Stake in BackJoy 3Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Sickle Cell Anemia Treatment So Successful in Kids That Trial Is Halted 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3
... Jan. 27 Bio-Reaction Industries, LLC (BRI),received the ... Special,Services by the Environmental Business Journal for 2008. ... Bio-Reactions progression as a worldwide leader of,bio-oxidation technology. ... amazing growth in 2008, increasing,revenue by 300% for ...
... 9% Over 2007 to $765.3 Million; Positive Operating Cash ... 27 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... year ended December 31, 2008. The Company reported total ... 31, 2008, which includes net product sales of $184.9 ...
... imperative of addressing chronic disease crisisWASHINGTON, Jan. 27 ... today urged President Obama and Congress to make ... components of reform efforts. Topping its list of ... leaders to realign incentives in the health care ...
... researchers say , , TUESDAY, Jan. 27 (HealthDay News) -- ... potential new method of promoting recovery from chronic stress ... "fight or flight" response. , The approach focuses on ... body,s major control systems. The HPA axis uses hormone ...
... Chest radiation indicates need for earlier screening, study notes, ... of female childhood cancer survivors under the age of ... treatment are not following the recommended advice to get ... , The recommendation suggests starting screening mammograms at age ...
... Calif., Jan. 27 Omnicell, Inc.,(Nasdaq: OMCL ) ... been awarded a five year contract by Duke University ... , Duke University Health ... Hospital, Duke Raleigh Hospital, and many other clinical,facilities. , ...
Cached Medicine News:Health News:Bio-Reaction Industries Recognized as Leader in Technology 2Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 2Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 3Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 4Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 5Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 6Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 7Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 8Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 9Health News:Amylin Pharmaceuticals Reports 2008 Financial Results 10Health News:National Partnership Releases Principles for Meaningful Health Reform 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 3Health News:Omnicell is Awarded Contract by Major National Academic Medical Center 2
BD Beaver Phaco slit blade, 3.2 mm, angled 45, bevel up. matte finish offers a precise incision which minimizes leakage during phaco procedures. Precise incision minimizes leakage during phaco proced...
BD Beaver DeBakey blade, 5 mm cutting width, sterile....
... testing of large oculomotor imbalances ... all standard trial frames. Offer ... thin optical quality acrylic and ... a display box. Available as ...
... only powered 6-inch dermatome on the market. ... adult hands or a small child's face ... to run more efficiently, thus the motor ... temperature is much cooler. The Electro-Dermatome is ...
Medicine Products: